Search

Your search keyword '"María Guirado-Risueño"' showing total 12 results
Start Over Author "María Guirado-Risueño"
12 results on '"María Guirado-Risueño"'

1. CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma

Author

Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, María L. Sánchez-León, Silvia Silva-Romeiro, Rocío Flores-Campos, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Lejeune Marylene, Tomás Álvaro-Naranjo, María Casanova-Espinosa, Antonio Rueda-Domínguez, Víctor Sánchez-Margalet, and Luis de la Cruz-Merino

Subjects
DLBCL, B cell lymphoma, recurrent/refractory disease, immune system, natural killer, CD8+ NK, Immunologic diseases. Allergy, RC581-607
Abstract

BackgroundDiffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in approximately 35-40% of the patients DLBCL relapses, and therefore, especially in this setting, the search for new prognostic and predictive biomarkers is an urgent need. Natural killer (NK) are effector cells characterized by playing an important role in antitumor immunity due to their cytotoxic capacity and a subset of circulating NK that express CD8 have a higher cytotoxic function. In this substudy of the R2-GDP-GOTEL trial, we have evaluated blood CD8+ NK cells as a predictor of treatment response and survival in relapsed/refractory (R/R) DLBCL patients.Methods78 patients received the R2-GDP schedule in the phase II trial. Blood samples were analyzed by flow cytometry. Statistical analyses were carried out in order to identify the prognostic potential of CD8+ NKs at baseline in R/R DLBCL patients.ResultsOur results showed that the number of circulating CD8+ NKs in R/R DLBCL patients were lower than in healthy donors, and it did not change during and after treatment. Nevertheless, the level of blood CD8+ NKs at baseline was associated with complete responses in patients with R/R DLBCL. In addition, we also demonstrated that CD8+ NKs levels have potential prognostic value in terms of overall survival in R/R DLBCL patients.ConclusionCD8+ NKs represent a new biomarker with prediction and prognosis potential to be considered in the clinical management of patients with R/R DLBCL.Clinical trial registrationhttps://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001620-29 EudraCT, ID:2014-001620-29.

Published
2024
Full Text
View/download PDF

2. Representatividad del Registro de Tumores Torácicos de España. Comparación de datos sociodemográficos con otros registros nacionales

Author

Cristina Candal-Pedreira, Alberto Ruano-Ravina, Enric Carcereny, Delvys Rodríguez-Abreu, María Guirado-Risueño, Rafael López-Castro, Bartomeu Massutí, Ana Blasco, Ana Laura Ortega, and Mariano Provencio

Subjects
Lung cancer, Spain, Cancer registry, Sex, Age, Public aspects of medicine, RA1-1270
Abstract

Resumen: Objetivo: En España, debido a la falta de datos, se creó un registro de cáncer de pulmón, el Registro de Tumores Torácicos (RTT), el cual debería demostrar su comparabilidad con los datos poblacionales para tener una representatividad adecuada. Con esta finalidad, se comparan las características sociodemográficas del RTT con los datos de incidencia de la Red de Registros de Cáncer (REDECAN) y de mortalidad del Instituto Nacional de Estadística (INE). Método: Se utilizaron las fuentes de datos de cáncer de pulmón disponibles hasta el momento: REDECAN e INE. De cada fuente se recogieron los casos de cáncer de pulmón globales y desagregados por sexo y por grupos de edad, y se compararon los datos para el periodo 2017-2020. Se calcularon las proporciones por sexo y grupo de edad del RTT respecto a ambas bases de datos (que recogen incidencia y mortalidad), para el periodo completo de estudio y desglosado por año. Resultados: Se incluyeron 17.109 casos incidentes de cáncer de pulmón incluidos en el RTT, 58.668 casos incidentes estimados de REDECAN y 88.083 muertes entre 2017 y 2020 del INE. En cuanto al sexo, las proporciones son muy similares entre las tres fuentes y las diferencias no superan el 4%. En cuanto a la edad, las diferencias no son elevadas, siendo mayores para los datos de mortalidad en el grupo de mayor edad del INE frente al RTT. Conclusiones: El RTT parece ser representativo de los casos de cáncer de pulmón diagnosticados en España para los años 2019 y 2020, tanto por sexo como por edad. Esto permite poder caracterizar con exactitud el estado de esta enfermedad, primera causa de muerte por cáncer en España, y que el análisis de resultados que se vayan a obtener del RTT pueda ser aplicado a los casos de cáncer de pulmón diagnosticados en nuestro país. Abstract: Objective: In Spain, due to the lack of data at national level a lung cancer registry, the Thoracic Tumour Registry (TTR), was created. Such registry should demonstrate comparability with population-based data to ensure representativeness at population level. The aim is to compare the socio-demographic characteristics of the TTR with incidence data from the Red de Registros de Cáncer (REDECAN) and mortality data from the Instituto Nacional de Estadística (INE). Method: Lung cancer data sources available to date, REDECAN and INE, were used. Lung cancer cases overall and disaggregated by sex and age groups were collected from each source of information and data were compared for the period 2017-2020. Sex and age group proportions of TTR were calculated for both databases (which collect incidence and mortality data), for the entire study period and broken down by year. Results: A total of 17,109 incident lung cancer cases from the TTR, 58,668 estimated incident cases from REDECAN and 88,083 deaths registered from INE between 2017 and 2020 were included. In terms of sex, the proportions are very similar between the three sources and the differences do not exceed 4%. In terms of age, the differences are not large, being larger for mortality data in the older age group from the INE versus the TTR. Conclusions: The TTR seems to be representative of lung cancer cases diagnosed in Spain between 2019 and 2020, both by sex and age. This allows us to accurately characterise the status of this disease, which is the leading cause of cancer death in Spain, and that the analysis of results obtained from the RTT can be applied to cases of lung cancer diagnosed in our country.

Published
2022
Full Text
View/download PDF

3. Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial

Author

Mariano Provencio, Luis de la Cruz-Merino, Delvys Rodriguez-Abreu, Tomás Álvaro, Marylène Lejeune, Carlos Jiménez-Cortegana, Natalia Palazón-Carrión, Alejandro Martin Garcia-Sancho, Esteban Nogales-Fernandez, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fatima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Antonio Rueda Dominguez, Maria Casanova-Espinosa, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Jorge Labrador, Antonio Salar-Silvestre, Laura Galvez-Carvajal, Margarita Sánchez-Beato, María Guirado-Risueño, Pablo Espejo-García, and Victor Sánchez-Margalet

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, and in cancer in general. It is well known that some immunomodulatory cells, such as myeloid derived suppressor cells (MDSCs) or regulatory T cells (Tregs), are recruited by tumors, jeopardizing antitumor immunosurveillance. In this work, we have studied blood levels of these immunosuppressive cells in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), prior to and along the course of the experimental rituximab, gemcitabine, dexamethasone, and cisplatin (R2-GDP) schedule, as a translational substudy of the R2-GDP-GOTEL trial (EudraCT Number: 2014-001620-29), which included lenalidomide as an immunomodulator.Methods Blood samples were taken before treatment, at cycle 3 and end of induction. Samples were analyzed by flow cytometry. Non-parametric tests were used. Mann-Whitney U test was used to compare basal cells distributions, and Wilcoxon test was considered to compare cells distribution at different times. Spearman test was performed to measure the degree of association between cell populations.Results In this study, MDSC and Treg circulating concentration was found increased in all patients compared with a healthy control group and decreased after treatment only in patients with longest overall survival (>24 months), reaching the levels of the healthy group. Likewise, the number of inhibited T lymphocytes expressing Programmed Death-1 (PD-1) were increased in peripheral blood from patients and decreased on the treatment, whereas activated T lymphocytes increased after therapy in those with better overall survival.Conclusions In conclusion, blood concentration of MDSCs and Treg cells may be good prognostic markers for overall survival after 2 years in R/R DLBCL. These results point to a possible role of these elements in the immunosuppression of these patients, as assessed by the circulating activated and inhibited T lymphocytes, and therefore, they may be considered as therapeutic targets in DLBCL.

Published
2021
Full Text
View/download PDF

4. Supplementary Table from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis

Author

Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, and Natalia Palazón-Carrión

Abstract

Supplementary Table from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis

Published
2023
Full Text
View/download PDF

5. Data from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis

Author

Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, and Natalia Palazón-Carrión

Abstract

Purpose:New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma.Patients and Methods:In the phase II R2-GDP trial, 78 patients unsuitable for autologous stem cell transplant received treatment with the following schedule: lenalidomide 10 mg Days (D)1–14, rituximab 375 mg/m2 D1, cisplatin 60 mg/m2 D1, gemcitabine 750 mg/m2 D1 and D8, and dexamethasone 20 mg D1–3, up to 6 cycles (induction phase), followed by lenalidomide 10 mg (or last lenalidomide dose received) D1–21 every 28 days (maintenance phase). Primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and monitorization of key circulating immune biomarkers (EU Clinical Trials Register number: EudraCT 2014-001620-29).Results:After a median follow-up of 37 months, ORR was 60.2% [37.1% complete responses (CR) and 23.1% partial responses (PR)]. Median OS was 12 months (47 vs. 6 months in CR vs. no CR); median PFS was 9 months (34 vs. 5 months in CR vs. no CR). In the primary refractory population, ORR was 45.5% (21.2% CR and 24.3% PR). Most common grade 3–4 adverse events were thrombocytopenia (60.2%), neutropenia (60.2%), anemia (26.9%), infections (15.3%), and febrile neutropenia (14.1%). Complete responses were associated with a sharp decrease in circulating myeloid-derived suppressor cells and regulatory T cells.Conclusions:R2-GDP schedule is feasible and highly active in R/R DLBCL, including the primary refractory population. Immune biomarkers showed differences in responders versus progressors.

Published
2023
Full Text
View/download PDF

6. Supplementary Data from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis

Author

Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, Josep Gumà-Padrò, Natividad Martínez-Banaclocha, Rubén Fernández-Álvarez, Guillermo Rodríguez-García, Fátima de la Cruz-Vicente, Eduardo Ríos-Herranz, Fernando Carnicero-González, Carlos Jiménez-Cortegana, Esteban Nogales-Fernández, Alejandro Martín García-Sancho, and Natalia Palazón-Carrión

Abstract

Supplementary Data from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis

Published
2023
Full Text
View/download PDF

7. Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-Cell lymphoma: final results of the R2-GDP-GOTEL trial and immune biomarker subanalysis

Author

Natalia Palazón-Carrión, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez-Cortegana, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fátima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Antonio Salar-Silvestre, Delvys Rodríguez-Abreu, Laura Gálvez-Carvajal, Jorge Labrador, María Guirado-Risueño, Daniel J. García-Domínguez, Lourdes Hontecillas-Prieto, Pablo Espejo-García, Isabel Fernández-Román, Mariano Provencio-Pulla, Margarita Sánchez-Beato, Marta Navarro, Lejeune Marylene, Tomás Álvaro-Naranjo, Maria Casanova-Espinosa, Victor Sánchez-Margalet, Antonio Rueda-Domínguez, and Luis de la Cruz-Merino

Subjects
Cancer Research, Limfomes, Tumors -- Tractament, Lymphoma, Non-Hodgkin, Treatment Outcome, Oncology, Antineoplastic Combined Chemotherapy Protocols, Marcadors bioquímics, Humans, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local, Rituximab, Lenalidomide, Biomarkers
Abstract

Purpose: New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma. Patients and Methods: In the phase II R2-GDP trial, 78 patients unsuitable for autologous stem cell transplant received treatment with the following schedule: lenalidomide 10 mg Days (D)1–14, rituximab 375 mg/m2 D1, cisplatin 60 mg/m2 D1, gemcitabine 750 mg/m2 D1 and D8, and dexamethasone 20 mg D1–3, up to 6 cycles (induction phase), followed by lenalidomide 10 mg (or last lenalidomide dose received) D1–21 every 28 days (maintenance phase). Primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and monitorization of key circulating immune biomarkers (EU Clinical Trials Register number: EudraCT 2014-001620-29). Results: After a median follow-up of 37 months, ORR was 60.2% [37.1% complete responses (CR) and 23.1% partial responses (PR)]. Median OS was 12 months (47 vs. 6 months in CR vs. no CR); median PFS was 9 months (34 vs. 5 months in CR vs. no CR). In the primary refractory population, ORR was 45.5% (21.2% CR and 24.3% PR). Most common grade 3–4 adverse events were thrombocytopenia (60.2%), neutropenia (60.2%), anemia (26.9%), infections (15.3%), and febrile neutropenia (14.1%). Complete responses were associated with a sharp decrease in circulating myeloid-derived suppressor cells and regulatory T cells. Conclusions: R2-GDP schedule is feasible and highly active in R/R DLBCL, including the primary refractory population. Immune biomarkers showed differences in responders versus progressors.

Published
2022

8. [Representativeness of the Spanish Thoracic Tumour Registry. Comparison of sociodemographic data with other national registries]

Author

Cristina, Candal-Pedreira, Alberto, Ruano-Ravina, Enric, Carcereny, Delvys, Rodríguez-Abreu, María, Guirado-Risueño, Rafael, López-Castro, Bartomeu, Massutí, Ana, Blasco, Ana Laura, Ortega, and Mariano, Provencio

Subjects
Lung Neoplasms, Spain, Incidence, Humans, Registries, Aged
Abstract

In Spain, due to the lack of data at national level a lung cancer registry, the Thoracic Tumour Registry (TTR), was created. Such registry should demonstrate comparability with population-based data to ensure representativeness at population level. The aim is to compare the socio-demographic characteristics of the TTR with incidence data from the Red de Registros de Cáncer (REDECAN) and mortality data from the Instituto Nacional de Estadística (INE).Lung cancer data sources available to date, REDECAN and INE, were used. Lung cancer cases overall and disaggregated by sex and age groups were collected from each source of information and data were compared for the period 2017-2020. Sex and age group proportions of TTR were calculated for both databases (which collect incidence and mortality data), for the entire study period and broken down by year.A total of 17,109 incident lung cancer cases from the TTR, 58,668 estimated incident cases from REDECAN and 88,083 deaths registered from INE between 2017 and 2020 were included. In terms of sex, the proportions are very similar between the three sources and the differences do not exceed 4%. In terms of age, the differences are not large, being larger for mortality data in the older age group from the INE versus the TTR.The TTR seems to be representative of lung cancer cases diagnosed in Spain between 2019 and 2020, both by sex and age. This allows us to accurately characterise the status of this disease, which is the leading cause of cancer death in Spain, and that the analysis of results obtained from the RTT can be applied to cases of lung cancer diagnosed in our country.

Published
2021

9. Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study

Author

Manuel Cobo, R. López-Castro, Amparo Sanchez-Gastaldo, Alberto Ruano-Ravina, Ana Laura Ortega, Bartomeu Massuti, Anna Estival, Oscar Juan, Enric Carcereny, Gretel Benítez, Mariano Provencio, Diego Pereiro Corbacho, Juana Oramas, Ana Blasco, Joaquín Mosquera-Martínez, Marta Belver, Carlos Guirao-Rubio, María Guirado-Risueño, Joaquim Bosch-Barrera, Edel del Barco Morillo, Jose Manuel Trigo, Delvys Rodriguez-Abreu, Manuel Domine, Carlos Aguado De La Rosa, Virginia Calvo de Juan, [Ruano-Ravina,A] Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain. [Ruano-Ravina,A] Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología and Salud Pública/CIBERESP), Madrid, Spain. [Ruano-Ravina,A] Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela - IDIS), Santiago de Compostela, Spain. [Provencio,M, Calvo de Juan,V] Department of Oncology, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain. [Carcereny,E, Estival,A] Medical Oncology Department, Catalan Institute of Oncology, Badalona- Germans Trias i Pujol Hospital B-ARGO group, Barcelona, Spain. [Rodríguez-Abreu,D, Benítez,G] Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain. [López-Castro,R, Belver,M] Servicio de Oncología, Sección de oncología médica, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. [Guirado-Risueño,M, Guirao-Rubio,C] Hospital de Elche, Elche, Spain, [Blasco,A] Hospital General de Valencia, Valencia, Spain. [Massutí,B] Hospital Universitario General de Alicante, Alicante, Spain. [Ortega,AL] Servicio de Oncología Médica. Complejo Hospitalario de Jaén, Jaén, Spain. [Cobo,M] Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain. [Mosquera-Martínez,J] Hospital Universitario de A Coruña, A Coruña, Spain. [Aguado de la Rosa,C] Department of Oncology, Clínico San Carlos Hospital, Madrid, Spain. [Bosch-Barrera,J] Girona Biomedical Research Institute (IDIBGI), Girona, Spain. [Bosch-Barrera,J] Department of Medical Sciences, Medical School, University of Girona, Girona, Spain. [Bosch-Barrera,J] Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Girona, Catalonia, Spain. [Sánchez-Gastaldo,A] Department of Oncology, Hospital Virgen del Rocío, Seville, Spain. [del Barco Morillo,E] Department of Oncology, Hospital de Salamanca, Slamanca, Spain. [Juan,Ó] Servicio Oncología Médica, Hospital Universitari i Politécnic La Fe, Valencia, Spain. [Dómine,M] Hospital Jiménez Díaz, Madrid, Spain. [Trigo,JM] Servicio de Oncología Médica y Unidad de Fases I, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Pereiro Corbacho,D] Hospital Universitario Álvaro Cunqueiro, Vigo, Spain. [Oramas,J] Hospital Universitario de Canarias, Santa Cruz Tenerife, Spain., Institut Català de la Salut, [Ruano-Ravina A] Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain. Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología and Salud Pública/CIBERESP), Madrid, Spain. Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela - IDIS), Santiago de Compostela, Spain. [Provencio M, Calvo de Juan V] Department of Oncology, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain. [Carcereny E, Estival A] Medical Oncology Department, Catalan Institute of Oncology, Badalona- Germans Trias i Pujol Hospital B-ARGO group, Barcelona, Spain. [Rodríguez-Abreu D, Benítez G] Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain. [López Castro R, Belver M] Servicio de Oncología, Sección de oncología médica, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. [Guirado Risueño M, Guirao-Rubio C] Hospital de Elche, Elche, Spain.[ Blasco A] Hospital General de Valencia, Valencia, Spain. [Massutí B] Hospital Universitario General de Alicante, Alicante, Spain. [Ortega Granados AL] Servicio de Oncología Médica. Complejo Hospitalario de Jaén, Jaén, Spain. [Cobo M] Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.[ Mosquera-Martínez J] Hospital Universitario de A Coruña, A Coruña, Spain. [Aguado C] Department of Oncology, Clínico San Carlos Hospital, Madrid, Spain. [Bosch-Barrera J] Girona Biomedical Research Institute (IDIBGI), Girona, Spain. Department of Medical Sciences, Medical School, University of Girona, Girona, Spain. Medical Oncology, Catalan Institute of Oncology, Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. [Sanchez Gastaldo A] Department of Oncology, Hospital Virgen del Rocío, Seville, Spain. [Del Barco Morillo E] Department of Oncology, Hospital de Salamanca, Salamanca, Spain. [Juan O] Servicio Oncología Médica, Hospital Universitari i Politécnic La Fe, Valencia, Spain. [Dómine M] Hospital Jiménez Díaz, Madrid, Spain. [Trigo J] Servicio de Oncología Médica y Unidad de Fases I, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Pereiro Corbacho D] Hospital Universitario Álvaro Cunqueiro, Vigo, Spain. [Oramas J] Hospital Universitario de Canarias, Santa Cruz Tenerife, Spain, and Hospital Universitari de Girona Dr Josep Trueta

Subjects
Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Signs and Symptoms, Digestive::Anorexia [Medical Subject Headings], Carcinoma pulmonar de células pequeñas, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Tobacco Use::Smoking [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Pulmons - Càncer, Weight loss, Lung neoplasms, Other subheadings::/diagnosis [Other subheadings], Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma [Medical Subject Headings], Fumar, Fumadors, Stage (cooking), conducta y mecanismos de la conducta::conducta::fumar [PSIQUIATRÍA Y PSICOLOGÍA], Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [Medical Subject Headings], Smoking, Small cell lung cancer (SCLC), Disciplines and Occupations::Natural Science Disciplines::Physics::Electronics [Medical Subject Headings], Anorexia, Oncology, Adenocarcinoma, Smoking status, Original Article, Sex, medicine.symptom, Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Asthenia [Medical Subject Headings], Behavior and Behavior Mechanisms::Behavior::Smoking [PSYCHIATRY AND PSYCHOLOGY], medicine.medical_specialty, Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [DISEASES], Neoplasias pulmonares, Otros calificadores::/diagnóstico [Otros calificadores], Check Tags::Male [Medical Subject Headings], Sexo, Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [Medical Subject Headings], enfermedades respiratorias::enfermedades respiratorias::neoplasias del tracto respiratorio::neoplasias pulmonares [ENFERMEDADES], Internal medicine, medicine, Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Body Weight::Body Weight Changes::Weight Loss [Medical Subject Headings], Lung cancer, business.industry, Anthropology, Education, Sociology and Social Phenomena::Social Sciences::Demography [Medical Subject Headings], Cancer, medicine.disease, Astenia, Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Sex Factors [HEALTH CARE], Check Tags::Female [Medical Subject Headings], Asthenia, Diferències entre sexes, Symptoms, calidad, acceso y evaluación de la atención sanitaria::calidad de la atención sanitaria::factores epidemiológicos::factores sexuales [ATENCIÓN DE SALUD], Síntomas, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries [Medical Subject Headings], Stage iv, business
Abstract

Càncer de pulmó; Fumar; Diferències entre sexes Cancer de pulmón; Fumar; Diferencias entre sexos Lung neoplasms; Smoking; Sex Factors Background: Lung cancer causes approximately 25% of all cancer deaths. Despite its relevance, few studies have analyzed differences by sex at the time of diagnosis in terms of symptoms, stage, age or smoking status. We aim to assess if there are differences between men and women on these characteristics at diagnosis. Methods: We analyzed the Thoracic Tumour Registry (TTR), sponsored by the Spanish Lung Cancer Group using a case-series design. This is a nationwide registry of lung cancer cases which started recruitment in 2016. For each case included, clinicians fulfilled an electronic record registering demographic data, symptoms, exposure to lung cancer risk factors, and treatment received in detail. We compared men and women using descriptive statistics. Results: A total of 13,590 participants took part in this study, 25.6% women. Women were 4 years younger than men (64 vs. 69), and men had smoked more frequently. Adenocarcinoma was the most frequent histological type in both sexes. Stage IV at diagnosis was 50.8% in women compared to 43.6% in men. Weight loss/anorexia/asthenia was the most frequent symptom in both sexes and there were no differences in the number of symptoms at diagnosis. There were no relevant differences in the frequency or number of symptoms by sex when non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) were analyzed separately. Smoking status did not appear to cause different lung cancer presentation in men compared to women. Conclusions: There seems to be no differences in lung cancer characteristics by sex at the time at diagnosis on stage, specific symptoms or number of symptoms. This research received funding from the Spanish Lung Cancer Group

Published
2021

10. Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice

Author

Santiago Aguín, María Victoria Baeza-Nadal, T. Sauri, Francisco García-Navalón, Dulce Rodríguez, Ana Fernández-Montes, Cristina Farriols, Jose Luis Fírvida, Joan Santamaría, Guillermo de Velasco, Patricia Martín, Manuel Cobo, María Guirado-Risueño, Vanessa G. Jerviz-Guía, Carmen Perezagua-Marín, and Rodolfo Chicas-Sett

Subjects
0301 basic medicine, medicine.medical_specialty, Constipation, Palliative care, medicine.drug_class, Narcotic Antagonists, Clinical Decision-Making, Receptors, Opioid, mu, Comorbidity, Medical Oncology, 03 medical and health sciences, 0302 clinical medicine, Opioid receptor, Neoplasms, medicine, Humans, Pharmacology (medical), Drug Interactions, Practice Patterns, Physicians', Intensive care medicine, Adverse effect, Evidence-Based Medicine, business.industry, Chronic pain, Age Factors, Cancer, Disease Management, Standard of Care, Cancer Pain, medicine.disease, Clinical Practice, 030104 developmental biology, Treatment Outcome, Oncology, Opioid, 030220 oncology & carcinogenesis, Drug Therapy, Combination, medicine.symptom, business, medicine.drug
Abstract

Management of chronic pain is crucial to improve the quality of life of cancer and palliative care patients. Opioid-based treatments used to control pain can be prolonged over time. Unfortunately, constipation is one of the most disturbing adverse effects of long-term use of opioids. Opioid-induced constipation (OIC) occurs when opioids bind to the specific receptors present in the gastrointestinal (GI) tract, and can affect any patients receiving chronic opioid therapy, including cancer patients. The limited efficacy of laxatives to treat OIC symptoms prompted the search for new therapeutic strategies. Peripherally acting μ-opioid receptor antagonists (PAMORAs) have recently emerged as new effective drugs for OIC management due to their specific binding to enteric μ-receptors. Little information is available on the use of PAMORAs in real-life practice for OIC treatment in cancer patients. In this paper, a panel of experts specializing in cancer and palliative care pools their clinical experience with PAMORAs in cancer patients presenting OIC and highlights the importance of timing and choice of therapy in achieving prompt OIC management and benefitting patients.

Published
2021

11. First analysis of the National Lung Cancer Register in Spain (RTT)

Author

Pilar Lianes, Manuel Domine, María Ángeles Sala, Miguel A. Muñoz, Carlos Camps, Miriam Dorta, Mariano Provencio-Pulla, Elvira Del Barco Morillo, Esther Noguerón, Bartomeu Massuti, Remei Blanco, Rosario Garcia Campelo, Julia Calzas, Ramon De Las Penas, Jose-Luis Gonzalez-Larriba, Delvys Rodriguez Abreu, J. Casal, Enric Carcereny, Joaquim Bosch, and María Guirado-Risueño

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, Cancer Research, medicine.medical_specialty, integumentary system, Oncology, Register (music), business.industry, Internal medicine, medicine, Lung cancer, medicine.disease, business
Abstract

e13608Background: The Spanish Lung Cancer Group (GECP) initiated a Tumor Thoracic Register (RTT) in September 2016 with the aim of evaluating accurate, basic data concerning this oncological pathol...

Published
2018
Full Text
View/download PDF

12. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

Author

Cristina Candal-Pedreira, Alberto Ruano-Ravina, Virginia Calvo de Juan, Manuel Cobo, José Manuel Trigo, Enric Carcereny, Marc Cucurull, Rafael López Castro, Eduardo Solís García, Amparo Sánchez-Gastaldo, Bartomeu Massutí, Delvys Rodríguez-Abreu, Anna Estival, María Guirado Risueño, María Pamiés Ramón, Rosario García Campelo, Guillermo Alonso-Jáudenes, Carlos Camps, Edel del Barco Morillo, Clara González Ojea, Manuel Dómine, Alfredo Sanchez-Hernandez, Joaquím Bosch-Barrera, María Ángeles Sala González, and Mariano Provencio

Subjects
Medicine
Abstract

Objectives The aim of the study was to ascertain the percentage of Spanish lung cancer cases that would fulfil the lung cancer screening inclusion criteria recommended by the United States Preventive Service Task Force (USPSTF) in 2013 and 2021. Methods A cross-sectional study was carried out. All lung cancer cases registered in the Thoracic Tumor Registry with data on date of birth, date of diagnosis, smoking habit, number of pack-years and time elapsed since smoking cessation were included. Results The study included 15 006 patients diagnosed with lung cancer in Spain between 2016 and 2022. Eligibility to participate in screening increased from 53.7% to 63.5% (an increase of 9.8%) according to the 2013 and 2021 recommendations, respectively. The percentage of eligible men rose by 9.2 percentage points with the 2021 versus 2013 recommendations, whereas this rise was 11.5 percentage points in women. Under the 2021 recommendations, 36.6% of women and 5.3% of men would not have fulfilled the screening inclusion criteria due to being never-smokers; 14.9% of women and 11.0% of men would not have fulfilled the age criterion; and 27.0% of ex-smokers among women compared to 35.6% among men would not have been eligible due to >15 years having elapsed since smoking cessation. Conclusions In Spain, over one-third of lung cancer cases could not be detected through screening, by virtue of not meeting the most recent inclusion criteria stated by the USPSTF. The degree of fulfilment in a potential nationwide screening programme should be analysed, with the aim of establishing inclusion criteria in line with each country's context.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results